In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India

Journal of Medical Microbiology

Volumn 60, Issue 7, 2011, Pages 961-967

  Chowdhary, Anuradha ^a   Randhawa, Harbans Singh ^a   Sundar, Gandhi ^a   Kathuria, Shallu ^a   Prakash, Anupam ^a   Khan, Ziauddin ^b   Sun, Sheng ^c   Xu, Jianping ^c  

^a UNIVERSITY OF DELHI   (India)

^b KUWAIT UNIVERSITY   (Kuwait)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CONTROLLED STUDY; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; FUNGUS ISOLATION; GENOTYPE; IN VITRO STUDY; INDIA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEROTYPE;

ANTIFUNGAL AGENTS; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; DRUG RESISTANCE, FUNGAL; ENVIRONMENTAL MICROBIOLOGY; GENOTYPE; HUMANS; INDIA; MOLECULAR SEQUENCE DATA;

EID: 79959504858     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.029025-0     Document Type: Article

References (48)

1. Aller, A. I., Martin-Mazuelos, E., Lozano, F., Gomez-Mateos, J., Steele-Moore, L., Holloway, W. J., Gutiérrez, M. J., Recio, F. J. & Espinel-Ingroff, A. (2000). Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob Agents Chemother 44, 1544-1548.
2. Armengou, A., Porcar, C., Mascaró, J. & García-Bragado, F. (1996). Possible development of resistance to fluconazole during suppressive therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis 23, 1337-1338.
3. Berg, J., Clancy, C. J. & Nguyen, M. H. (1998). The hidden danger of primary fluconazole prophylaxis for patients with AIDS. Clin Infect Dis 26, 186-187.
4. Birley, H. D., Johnson, E. M., McDonald, P., Parry, C., Carey, P. B. & Warnock, D. W. (1995). Azole drug resistance as a cause of clinical relapse in AIDS patients with cryptococcal meningitis. Int J STD AIDS 6, 353-355.
5. Byrnes, E. J., III, Li, W., Lewit, Y., Ma, H., Voelz, K., Ren, P., Carter, D. A., Chaturvedi, V., Bildfell, R. J. & other authors (2010). Emergence and pathogenicity of highly virulent Cryptococcus gattii genotypes in the northwest United States. PLoS Pathog 6, e1000850.
6. Calvo, B. M., Colombo, A. L., Fischman, O., Santiago, A., Thompson, L., Lazera, M., Telles, F., Fukushima, K., Nishimura, K. & other authors (2001). Antifungal susceptibilities, varieties, and electrophoretic karyotypes of clinical isolates of Cryptococcus neoformans from Brazil, Chile, and Venezuela. J Clin Microbiol 39, 2348-2350.
7. Casadevall, A. & Perfect, J. R. (1998). Cryptococcus neoformans. Washington, DC: American Society for Microbiology.
8. Chakrabarti, A., Sharma, A., Sood, A., Grover, R., Sakhuja, V., Prabhakar, S. & Varma, S. (2000). Changing scenario of cryptococcosis in a tertiary care hospital in north India. Indian J Med Res 112, 56-60.
9. Chen, S., Sorrell, T., Nimmo, G., Speed, B., Currie, B., Ellis, D., Marriott, D., Pfeiffer, T., Parr, D. & other authors (2000). Epidemiology and host-and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Clin Infect Dis 31, 499-508.
10. CLSI (2008). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, 3rd edn. Approved Standard. M27-A3. Wayne, PA: Clinical and Laboratory Standards Institute.
11. Costa, A. K., Sidrim, J. J., Cordeiro, R. A., Brilhante, R. S., Monteiro, A. J. & Rocha, M. F. (2010). Urban pigeons (Columba livia) as a potential source of pathogenic yeasts: a focus on antifungal susceptibility of Cryptococcus strains in Northeast Brazil. Mycopathologia 169, 207-213.
12. Currie, B. P., Ghannoum, M., Bessen, L. & Casadevall, A. (1995). Decreased fluconazole susceptibility of a relapse Cryptococcus neoformans isolate after fluconazole treatment. Infect Dis Clin Pract 4, 318-319.
13. Davey, K. G., Johnson, E. M., Holmes, A. D., Szekely, A. & Warnock, D. W. (1998). In-vitro susceptibility of Cryptococcus neoformans isolates to fluconazole and itraconazole. J Antimicrob Chemother 42, 217-220.
14. Fernandes, O. de F. L., Passos, X. S., Souza, L. K. H., Miranda, A. T. B., Cerqueira, C. H. P. V. & Silva, M. do R. R. (2003). In vitro susceptibility characteristics of Cryptococcus neoformans varieties from AIDS patients in Goiânia, Brazil. Mem Inst Oswaldo Cruz 98, 839-841.
15. Franzot, S. P. & Hamdan, J. S. (1996). In vitro susceptibilities of clinical and environmental isolates of Cryptococcus neoformans to five antifungal drugs. Antimicrob Agents Chemother 40, 822-824.
16. Gomez-Lopez, A., Zaragoza, O., Dos Anjos Martins, M., Melhem, M. C., Rodriguez-Tudela, J. L. & Cuenca-Estrella, M. (2008). In vitro susceptibility of Cryptococcus gattii clinical isolates. Clin Microbiol Infect 14, 727-730.
17. Hagen, F., Illnait-Zaragozi, M. T., Bartlett, K. H., Swinne, D., Geertsen, E., Klaassen, C. H. W., Boekhout, T. & Meis, J. F. (2010). In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary and environmental Cryptococcus gattii isolates. Antimicrob Agents Chemother 54, 5139-5145.
18. Hiremath, S. S., Chowdhary, A., Kowshik, T., Randhawa, H. S., Sun, S. & Xu, J. (2008). Long-distance dispersal and recombination in environmental populations of Cryptococcus neoformans var. grubii from India. Microbiology 154, 1513-1524.
19. Iqbal, N., DeBess, E. E., Wohrle, R., Sun, B., Nett, R. J., Ahlquist, A. M., Chiller, T. & Lockhart, S. R. for the Cryptococcus gattii Public Health Working Group (2010). Correlation of genotype and in vitro susceptibilities of Cryptococcus gattii strains from the Pacific Northwest of the United States. J Clin Microbiol 48, 539-544.
20. Jain, N., Wickes, B. L., Keller, S. M., Fu, J., Casadevall, A., Jain, P., Ragan, M. A., Banerjee, U. & Fries, B. C. (2005). Molecular epidemiology of clinical Cryptococcus neoformans strains from India. J Clin Microbiol 43, 5733-5742.
21. Khan, Z. U., Randhawa, H. S., Kowshik, T., Chowdhary, A. & Chandy, R. (2007). Antifungal susceptibility of Cryptococcus neoformans and Cryptococcus gattii isolates from decayed wood of trunk hollows of Ficus religiosa and Syzygium cumini trees in north-western India. J Antimicrob Chemother 60, 312-316.
22. Khan, Z. U., Randhawa, H. S., Chehadeh, W., Chowdhary, A., Kowshik, T. & Chandy, R. (2009). Cryptococcus neoformans serotype A and Cryptococcus gattii serotype B isolates differ in their susceptibilities to fluconazole and voriconazole. Int J Antimicrob Agents 33, 559-563.
23. Khanna, N., Chandramuki, A., Desai, A., Ravi, V., Santosh, V., Shankar, S. K. & Satishchandra, P. (2000). Cryptococcosis in the immunocompromised host with special reference to AIDS. Indian J Chest Dis Allied Sci 42, 311-315.
24. Kidd, S. E., Hagen, F., Tscharke, R. L., Huynh, M., Bartlett, K.H., Fyfe, M., MacDougall, L., Boekhout, T., Kwon-Chung, K. J. & Meyer, W. (2004). A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci U S A 101, 17258-17263.
25. Kwon-Chung, K. J., Boekhout, T., Fell, J. W. & Diaz, M. (2002). Proposal to conserve the name Cryptocoocus gattii against C. hondurianus and C. bacillisporus (Basidiomycota, Hymenomycetes, Tremellomycetidae). Taxon 51, 804-806.
26. Lakshmi, V., Sudha, T., Teja, V. D. & Umabala, P. (2007). Prevalence of central nervous system cryptococcosis in human immunodeficiency virus reactive hospitalized patients. Indian J Med Microbiol 25, 146-149.
27. Meyer, W., Marszewska, K., Amirmostofian, M., Igreja, R.P., Hardtke, C., Methling, K., Viviani, M. A., Chindamporn, A., Sukroongreung, S. & other authors (1999). Molecular typing of global isolates of Cryptococcus neoformans var. neoformans by polymerase chain reaction fingerprinting and randomly amplified polymorphic DNA-a pilot study to standardize techniques on which to base a detailed epidemiological survey. Electrophoresis 20, 1790-1799.
28. Meyer, W., Aanensen, D. M., Boekhout, T., Cogliati, M., Diaz, M. R., Esposto, M. C., Fisher, M., Gilgado, F., Hagen, F. & other authors (2009). Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Med Mycol 47, 561-570.
29. Mitchell, D. H., Sorrell, T. C., Allworth, A. M., Heath, C. H., McGregor, A. R., Papanaoum, K., Richards, M. J. & Gottlieb, T. (1995). Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. Clin Infect Dis 20, 611-616.
30. Moraes, E. M., Prímola, N. S. & Hamdan, J. S. (2003). Antifungal susceptibility of clinical and environmental isolates of Cryptococcus neoformans to four antifungal drugs determined by two techniques. Mycoses 46, 164-168.
31. Morgan, J., McCarthy, K. M., Gould, S., Fan, K., Arthington-Skaggs, B., Iqbal, N., Stamey, K., Hajjeh, R. A., Brandt, M. E. & Gauteng Cryptococcal Surveillance Initiative Group (2006). Cryptococcus gattii infection: characteristics and epidemiology of cases identified in a South African province with high HIV seroprevalence, 2002-2004. Clin Infect Dis 43, 1077-1080.
32. Orni-Wasserlauf, R., Izkhakov, E., Siegman-Igra, Y., Bash, E., Polacheck, I. & Giladi, M. (1999). Fluconazole-resistant Cryptococcus neoformans isolated from an immunocompetent patient without prior exposure to fluconazole. Clin Infect Dis 29, 1592-1593.
33. Paugam, A., Dupouy-Camet, J., Blanche, P., Gangneux, J. P., Tourte-Schaefer, C. & Sicard, D. (1994). Increased fluconazole resistance of Cryptococcus neoformans isolated from a patient with AIDS and recurrent meningitis. Clin Infect Dis 19, 975-976.
34. Perfect, J. R., Dismukes, W. E., Dromer, F., Goldman, D. L., Graybill, J. R., Hamill, R. J., Harrison, T. S., Larsen, R. A., Lortholary, O. & other authors (2010). Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 50, 291-322.
35. Randhawa, H. S., Kowshik, T., Preeti Sinha, K., Chowdhary, A., Khan, Z. U., Yan, Z., Xu, J. & Kumar, A. (2006). Distribution of Cryptococcus gattii and Cryptococcus neoformans in decayed trunk wood of Syzygium cumini trees in north-western India. Med Mycol 44, 623-630.
36. Randhawa, H. S., Kowshik, T., Chowdhary, A., Preeti Sinha, K., Khan, Z. U., Sun, S. & Xu, J. (2008). The expanding host tree species spectrum of Cryptococcus gattii and Cryptococcus neoformans and their isolations from surrounding soil in India. Med Mycol 46, 823-833.
37. Scholer, H. J. & Polak, A. (1984). Resistance to systemic antifungal agents. In Antimicrobial Drug Resistance, pp. 393-460. Edited by L. E. Bryan. Orlando, FL: Academic Press.
38. Soares, M. C., Paula, C. R., Dias, A. L., Caseiro, M. M. & Costa, S. O. (2005). Environmental strains of Cryptococcus neoformans variety grubii in the city of Santos, SP, Brazil. Rev Inst Med Trop Sao Paulo 47, 31-36.
39. Souza, L. K., Fernandes, O. de F. L., Kobayashi, C. C., Passos, X. S., Costa, C. R., Lemos, J. A., Souza-Júnior, A. H. & Silva, M. do R. R. (2005). Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiânia city, Goiás, Brazil. Rev Inst Med Trop Sao Paulo 47, 253-256.
40. Speed, B. & Dunt, D. (1995). Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis 21, 28-34, discussion 35-36.
41. Tay, S. T., Tanty Haryanty, T., Ng, K. P., Rohani, M. Y. & Hamimah, H. (2006). In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs. Mycoses 49, 324-330.
42. Thakur, R., Sarma, S. & Kushwaha, S. (2008). Prevalence of HIVassociated cryptococcal meningitis and utility of microbiological determinants for its diagnosis in a tertiary care center. Indian J Pathol Microbiol 51, 212-214.
43. Thompson, G. R., III, Wiederhold, N. P., Fothergill, A. W., Vallor, A. C., Wickes, B. L. & Patterson, T. F. (2009). Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agents Chemother 53, 309-311.
44. Trilles, L., Fernández-Torres, B., Lazéra, M. dos S., Wanke, B. & Guarro, J. (2004). In vitro antifungal susceptibility of Cryptococcus gattii. J Clin Microbiol 42, 4815-4817.
45. van Duin, D., Cleare, W., Zaragoza, O., Casadevall, A. & Nosanchuk, J. D. (2004). Effects of voriconazole on Cryptococcus neoformans. Antimicrob Agents Chemother 48, 2014-2020.
46. Varma, A. & Kwon-Chung, K. J. (2010). Heteroresistance of Cryptococcus gattii to fluconazole. Antimicrob Agents Chemother 54, 2303-2311.
47. Witt, M. D., Lewis, R. J., Larsen, R. A., Milefchik, E. N., Leal, M. A., Haubrich, R. H., Richie, J. A., Edwards, J. E., Jr & Ghannoum, M. A. (1996). Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing. Clin Infect Dis 22, 322-328.
48. Yildiran, S. T., Saracli, M. A., Fothergill, A. W. & Rinaldi, M. G. (2000). In vitro susceptibility of environmental Cryptococcus neoformans variety neoformans isolates from Turkey to six antifungal agents, including SCH56592 and voriconazole. Eur J Clin Microbiol Infect Dis 19, 317-319.